Development of a decision-making biomarker for CRTH2 antagonism in clinical studies

New Horizons in Translational Medicine

Volumn 2, Issue 4-5, 2015, Pages 118-125

  Strasser, Daniel S ^a   Farine, Hervé ^a   Holdener, Martin ^a   Zisowsky, Jochen ^a   Roscher, René ^a   Hoerner, Julie ^a   Gehin, Martine ^a   Sidharta, Patricia N ^a   Dingemanse, Jasper ^a   Groenen, Peter M A ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

ACT 453859; CRTH2; Decision making biomarker; Flow cytometry; GPR44; PTGDR2; Receptor internalization; Setipiprant

Indexed keywords

ACT 453859; ALPHA4 INTEGRIN; CD203C ANTIGEN; CELL SURFACE MARKER; CHEMOKINE RECEPTOR CCR3; CRTH2 ANTAGONIST; CRTH2 RECEPTOR; INTERLEUKIN 13; PROSTAGLANDIN D2; RECEPTOR BLOCKING AGENT; SETIPIPRANT; UNCLASSIFIED DRUG;

ARTICLE; BASOPHIL; CELL SPECIFICITY; CONTROLLED STUDY; DECISION MAKING; EC50; EOSINOPHIL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNALIZATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR DENSITY; TH2 CELL;

EID: 84936140336     PISSN: None     EISSN: 23075023     Source Type: Journal    
DOI: 10.1016/j.nhtm.2015.05.001     Document Type: Article

References (34)

1. Bell S., Anderson L., Nugent C., Klopfenstein N., Eberhardt C., Carter L.L., Kass C., Rojas-Caro S., Burgess L., Bergstrom B., Miller S Safety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies 2010, European Respiratory Society, Barcelona.
2. Choy D.F., Modrek B., Abbas A.R., Kummerfeld S., Clark H.F., Wu L.C., Fedorowicz G., Modrusan Z., Fahy J.V., Woodruff P.G., Arron J.R. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J. Immunol. 2011, 186:1861-1869.
3. M., Gehin, D.S., Strasser, J., Zisowsky, H., Farine, P.M., Groenen, J., Dingemanse, P.N., Sidharta, 2015. A novel CRTH2 antagonist: single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects. J. Clin. Pharmacol., 55, 787-797.
4. Gervais F.G., Cruz R.P, Chateauneuf A., Gale S., Sawyer N., Nantel F., Metters K.M., O'Neill G.P Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J. Allergy Clin. Immunol. 2001, 108:982-988.
5. Hirai H., Tanaka K., Yoshie O., Ogawa K., Kenmotsu K., Takamori Y., Ichimasa M., Sugamura K., Nakamura M., Takano S., Nagata K. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 2001, 193:255-261.
6. Holgate S.T., Broide D. New targets for allergic rhinitis-a disease of civilization. Nat. Rev. Drug Discov. 2003, 2:902-914.
7. Iwasaki M., Nagata K., Takano S., Takahashi K., Ishii N., Ikezawa Z. Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. J. Investig. Dermatol. 2002, 119:609-616.
8. Krug N., Gupta A., Badorrek P., Koenen R., Mueller M., Pivovarova A., Hilbert J., Wetzel K., Hohlfeld J.M., Wood C. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2014, 133:414-419.
9. Luna-Gomes T., Magalhaes K.G., Mesquita-Santos F.P., Bakker-Abreu I., Samico R.F., Molinaro R., Calheiros A.S., Diaz B.L., Bozza P.T., Weller P.F., Bandeira-Melo C. Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation. J. Immunol. 2011, 187:6518-6526.
10. S., Mangialaio. Study of ACT-129968 in Adult Patients with Seasonal Allergic Rhinitis (SAR), clinicaltrials.gov, NCT01241214, 2014.
11. MerckSharpDohme. A Two-part Study of the Effects of MK-1029 in Allergen-challenged Asthmatics (MK-1029-003 AM1), clinicaltrials.gov, NCT01343407, 2014.
12. Monneret G., Li H., Vasilescu J., Rokach J., Powell W.S. 15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J. Immunol. 2002, 168:3563-3569.
13. Monneret G., Boumiza R., Gravel S., Cossette C., Bienvenu J., Rokach J., Powell W.S. Effects of prostaglandin D(2) and 5-lipoxygenase products on the expression of CD203c and CD11b by basophils. J. Pharmacol. Exp. Ther. 2005, 312:627-634.
14. Nagata K., Tanaka K., Ogawa K., Kemmotsu K., Imai T., Yoshie O., Abe H., Tada K., Nakamura M., Sugamura K, Takano S. Selective expression of a novel surface molecule by human Th2 cells in vivo. J. Immunol. 1999, 162:1278-1286.
15. Nagata K., Hirai H., Tanaka K., Ogawa K., Aso T., Sugamura K., Nakamura M., Takano S. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999, 459:195-199.
16. Patou J., Holtappels G., Affleck K., Gevaert P., Perez-Novo C., Van Cauwenberge P., Bachert C. Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue. J. Inflamm. (Lond) 2009, 6:11.
17. Perez-Novo C.A., Holtappels G., Vinall S.L., Xue L., Zhang N., Bachert C., Pettipher R. CRTH2 mediates the activation of human Th2 cells in response to PGD(2) released from IgE/anti-IgE treated nasal polyp tissue. Allergy 2010, 65:304-310.
18. Pettipher R., Hansel T.T., Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 2007, 6:313-325.
19. Pettipher R., Vinall S.L., Xue L., Speight G., Townsend E.R., Gazi L., Whelan C.J., Armer R.E., Payton M.A., Hunter M.G. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J. Pharmacol. Exp. Ther. 2012, 340:473-482.
20. S., Saini. Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines, clinicaltrials.gov, NCT02031679, 2014.
21. Schuligoi R., Schmidt R., Geisslinger G., Kollroser M., Peskar B.A., Heinemann A. PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. Biochem. Pharmacol. 2007, 74:107-117.
22. Schuligoi R., Sedej M., Waldhoer M., Vukoja A., Sturm E.M., Lippe I.T., Peskar B.A., Heinemann A. Prostaglandin H2 induces the migration of human eosinophils through the chemoattractant receptor homologous molecule of Th2 cells, CRTH2. J. Leukoc. Biol. 2009, 85:136-145.
23. Shirasaki H., Kikuchi M., Kanaizumi E., Himi T. Accumulation of CRTH2-positive leukocytes in human allergic nasal mucosa. Ann. Allergy Asthma Immunol. 2009, 102:110-115.
24. Stearns B.A., King C.D., Brittain J.E., Holme K.R. DP2 Antagonist and Uses Thereof 2011, W.I.P. Organization, WO 2011/017201 A2.
25. Stinson S.E., Amrani Y, Brightling C.E. D prostanoid receptor 2 (chemoattractant receptor-homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells. J. Allergy Clin. Immunol. 2015, 135:395-406.
26. St Ledger K., Agee S.J., Kasaian M.T., Forlow S.B., Durn B.L., Minyard J., Lu Q.A., Todd J., Vesterqvist O., Burczynski M.E. Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system. J. Immunol. Methods 2009, 350:161-170.
27. Straumann A., Bauer M., Fischer B., Blaser K., Simon H.U. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J. Allergy Clin. Immunol. 2001, 108:954-961.
28. Straumann A., Hoesli S., Bussmann C., Stuck M., Perkins M., Collins L.P., Payton M., Pettipher R., Hunter M., Steiner J, Simon H.U. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013, 68:375-385.
29. Thomas J., Gorski K., Evangelista C., Belouski S.S., Banfield C., Ferbas J. Development and Implementation of a CRTH2 Receptor Internalization Assay for Assessment of Target Coverage by a Small Molecule CRTH2/DP Receptor Antagonist 2011, FOCIS, Washington D.C.
30. Ulven T., Kostenis E. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin. Ther. Pat. 2010, 20:1505-1530.
31. J., Vestbo. Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus), clinicaltrials.gov, NCT00690482, 2014.
32. Vinall S.L., Townsend E.R., Pettipher R. A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+ CD4+ T helper type 2 lymphocytes. Immunology 2007, 121:577-584.
33. Xue L., Gyles S.L., Barrow A., Pettipher R. Inhibition of PI3K and calcineurin suppresses chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)-dependent responses of Th2 lymphocytes to prostaglandin D(2). Biochem. Pharmacol. 2007, 73:843-853.
34. Yoshimura-Uchiyama C., Iikura M., Yamaguchi M., Nagase H., Ishii A., Matsushima K., Yamamoto K., Shichijo M., Bacon K.B, Hirai K. Differential modulation of human basophil functions through prostaglandin D2 receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clin. Exp. Allergy 2004, 34:1283-1290.